USP15 and neoplasm: Here, using in vivo CRISPR screens, the authors integrate human cancer genomics and mouse models, identifying that loss of USP15 or SCAF1 accelerates tumor development and leads to reduced inflammatory responses and increased sensitivity to PARP inhibition and Gemcitabine.